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Abstract In order to visualize the activity of the cAMP-
dependent protein kinase (PKA) in living cells, we have 
constructed a new fluorescence PKA substrate by conjugating a 
fluorescence probe to a partial amino acid sequence of PKA 
regulatory domain II which contains a specific autophosphoryla-
tion site. The fluorescent peptide was cell-permeable and became 
phosphorylated when the intracellular cAMP concentration was 
increased, resulting in a decrease in its fluorescence intensity. In 
NG108-15 cells, PKA activity was localized to the cytosol 
around the nucleus. In cultured hippocampal neurons, addition of 
L-glutamate caused PKA activation associated with increase of 
the cellular cAMP. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cyclic A M P is one of the main second messengers and 
plays an important role as a signal transducer in many cellular 
activities, the signal being transmitted by activation of cAMP-
dependent protein kinase (PKA). P K A regulates specific gene 
expression by phosphorylating specific nuclear proteins, such 
as the cAMP-responsive element (CRE) binding protein 
(CREB), which, in turn, stimulates transcription of the gene 
corresponding C R E [1]. P K A is thought either to initiate long 
term potentiation (LTP), a model for memory formation [2], 
or to modulate its late phase [3]. Using fluorescent conjugates 
of exogenous PKA, it has been shown that an increase in 
intracellular c A M P levels results in dissociation of the cata-
lytic domain of P K A from the regulatory domain, with the 
catalytic domain translocating into the nucleus [4—7]. More-
over, compartmentalization of P K A may be important in the 
phosphorylation of specific target proteins [8]. However, the 
dynamics of endogenous P K A are currently unknown. A suit-
able means for investigating this would be an imaging system 
using a fluorescent substrate. We recently developed such an 
imaging system to measure the intracellular activity of Ca 2 + / 
calmodulin-dependent protein kinase II (CaMKII) , using a 
cell-permeable fluorescent C a M K I I substrate [9]. 
In the present study, in order to visualize the dynamics of 
endogenous P K A activity in living cells, we constructed a new 
cell-permeable fluorescent P K A substrate, consisting of a flu-
orescent probe and an amino acid sequence comprising part 
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of regulatory domain II (RII) of PKA, that contains a specific 
serine autophosphorylat ion site. Using this fluorescence con-
jugate and fluorescence microscopy image processing, we have 
successfully observed dynamic features of endogenous P K A 
activation in neural cells and glutamate-induced PKA activa-
tion in cultured hippocampal neurons. 
2. Materials and methods 
2.1. Materials 
6-Acryloyl-2-dimethlaminonaphthalene (acrylodan) was obtained 
from Molecular Probes, OR, USA, Ar-(7-dimethylamino-4-methylcou-
marinyl)maleimide (DACM) from Teika Seiyaku, Toyama, Japan, 
calpeptin from Funakoshi, Tokyo, Japan, H-89 from Seikagaku, To-
kyo, Japan, and Rp-cAMPS from Research Biochemicals Internation-
al, MA, USA. FK506 was a gift from the Fujisawa Pharmaceutical 
Company, Osaka, Japan. 
2.2. Preparation of fluorescent substrates 
Peptide and phosphopeptide were synthesized using the Fmoc solid-
phase method [10,11]. Fluorescent substrates were constructed by con-
jugating the synthetic peptide, via a Cys residue, to either acrylodan 
or DACM (Table 1), as follows: 1 ml of a 2.5 mM aqueous peptide 
solution was mixed with 0.525 ml of 4.8 mM fluoroprobe solution in 
CH3CN and 0.1 ml of 100 mM NaHCOs and left at room temper-
ature for 24 h in the dark, then the labelled peptide was purified by 
HPLC on a C8 column, as described below. The structures of the 
fluorescent peptides were confirmed by FAB-mass spectrometry, 
which showed a 1:1 molar coupling of fluoroprobe and peptide. 
2.3. HPLC of fluorescent peptides 
The fluorescent peptide (up to 0.5 mg) was applied to a C8 column 
(Aquapore RP-300, 7 um pore size, 30X4.6 mm, Applied Biosystems, 
CA, USA) and eluted using a 20 ml linear gradient consisting of 10-
50% CH3CN in 0.1% trifluoroacetic acid at a flow rate of 1 ml/min. 
The fluorescent peptide was detected by absorption at 215 nm and by 
fluorescence (524 nm emission, 366 nm excitation). 
2.4. Cell lysate 
Cell lysates were prepared by homogenization of neuroblastoma or 
neuroblastoma X glioma cells in 10 mM Tris-HCl, pH 7.5, 1 mM 
EGTA, 1 mM EDTA, 0.5 mM dithiothreitol, 0.1 mM phenylmethyl-
sulfonylfluoride, 5 mg/1 of leupeptin, and 20 mg/1 of trypsin inhibitor, 
followed by centrifugation at lOOOOXg for 15 min, as described by 
Hashimoto et al. [12]. 
2.5. Cell cultures for single cell analysis 
NG108-15 (neuroblastoma X glioma cell line) cells (5X104) in 2 ml 
of DMEM containing 5% FCS, 100 uM hypoxanthine and 16 uM 
thymidine were cultured at 37°C for 24 h in 35 mm glass-bottom 
microwell dishes, coated with poly-D-lysine (MatTek, MA, USA) 
and used after 2-10 days of serum depletion. Primary cultures of rat 
hippocampal neurons were prepared from 18-day embryonic rat 
brain, and cultured on glass coverslips for 7 days, as described pre-
viously [13]. 
2.6. Kinase assay in living cells 
The cells were loaded with the fluorescent substrate conjugate by 
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incubation with 100 ug/ml of ARII or 25 ug/ml of DRII (Table 1) in 
balanced salt solution, pH 7.3, consisting of 130 mM NaCl, 5.4 mM 
KC1, 20 mM HEPES, 5.5 mM glucose, 1.8 mM CaCl2, 0.8 mM 
MgS04 and 1 U.M calpeptin, a protease inhibitor, (solution A) for 
30-60 min at 23°C. The substrate-loaded cells were conditioned by 
passage of solution A (1.4 ml/min) at 30°C, then exposed to the 
stimulating drug; the fluorescence of the stained cells was then meas-
ured using 360 nm or 400 nm excitation for ARII or DRII, respec-
tively, and subjected to image analysis, using an image processor 
(Argus 100 or Argus 50, Hamamatsu Photonics, Shizuoka, Japan). 
Pseudo color ratio images were obtained by dividing each fluorescent 
image, recorded at a given time-point, by a reference image recorded 
before stimulant administration. 
2.7. Quantitation of cellular cAMP 
Cellular cAMP, extracting using 65% ethanol, was measured using 
the Biotrak cAMP El A System (Amarsham). The values were ana-
lyzed by F-test to compare variances. 
3. Results and discussion 
3.1. Fluorescent PKA substrate conjugate 
We have developed a cell-permeable fluorescent substrate 
which can be used to measure the real-time activity of PKA. 
A 19-residue peptide (RII19, Table 1), residues 81-99 of reg-
ulatory domain II of bovine cardiac muscle PKA, produced 
by digestion with S. aureus protease and which contains an 
autophosphorylatable Ser residue, is known to be readily 
phosphorylated by PKA [14]. Enz et al. replaced Cys-97 
with Ala and found that the resultant peptide was still readily 
phosphorylated by PKA [15]. In the present work, we started 
Table 1 
Structure of fluorescent PKA peptide substrate conjugates and re-
lated peptides 
81 91 
R1I19" 
ARII 
DRII 
RatRII19b 
DLDVPIPGRFDRRVSVCAE 
DLDVPIPGRFDRRVSVAAC-Acryl odan 
DLDVPLPAKADRRVSVAAC - DACM 
DL EVPIPAKFTRRVSVC AE 
aRII19: sequence from bovine cardiac muscle [20]. 
bRII19: sequence from rat skeletal muscle [21]. 
with this latter peptide and replaced the C-terminal residue, 
Glu-99, with Cys, then used this residue to conjugate the 
peptide to the fluorescent probe, acrylodan. The resultant flu-
orescent peptide, ARII (Table 1) was also readily phosphory-
lated by PKA, the 524 nm fluorescence emission peak (exci-
tation at 366 nm) of acrylodan being decreased on 
phosphorylation; when 15 |0.g/ml of ARII was incubated 
with 5-10 |ig/ml of purified PKA in 10 mM MgAc2, 1 mM 
EGTA and 0.5 mM ATP, pH 7.5, little, or no, phosphoryla-
tion occurred until 0.5 mM cAMP was added (Fig. 1A). 
Under the conditions used, the ARII fluorescence decreased 
by 3.3% on phosphorylation. To determine whether our sys-
tem using changes in ARII fluorescence could be applied not 
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Fig. 1. Cyclic AMP-mediated ARII phosphorylation by purified PKA (A) or neuroblastoma cell lysate (B). Fifteen ug/ml of ARII was pre-in-
cubated with 1 mM EGTA, 10 mM MgAc2, 0.5 mM ATP, 50 mM HEPES, pH 7.5, at 25°C for 2 min and 10 ug/ml of purified PKA (holoen-
zyme from bovine heart, Sigma, P-5511) or neuro2A neuroblastoma cell lysate (final concentration of 40 ug protein/ml) was added. Two mi-
nutes later, phosphorylation was initiated by addition of 0.5 mM cAMP. The fluorescence intensity decreased gradually by phosphorylation 
following the straight drop by reagent dilution. The left trace shows the time course of the fluorescence intensity and the right trace the HPLC 
profile of the experimental material compared with standard phosphorylated peptide conjugate. The phosphorylated substrate conjugate eluted 
at the same position as standard phosphorylated ARII on HPLC analysis. The presence of the phosphoserine group in the isolated product 
was confirmed by amino acid sequencing. 
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Fig. 2. (A): ARII loading of living neural cell lines. The ARII fluorescence image is shown on the left, while the right panel shows the fluores-
cence image of the nuclei of the same cells, overlapped by a transmitted light image of the cells. Cell nuclei were stained using 5 (ig/ml of 
Hoechst 33342 (Molecular Probes, OR, USA) in solution A for 10 min. The white bar corresponds to 10 um. (B and C): Activation of PKA 
in ARII-loaded NG108-15 cells by stimulation with forskolin. The upper left and right panels in B show transmitted light and fluorescence im-
ages of the cells, respectively. At time 0, the pre-loaded cells were stimulated by exposure to 10 uM forskolin for 30 s. The time course of the 
fluorescence ratios in the colored squares in the upper right panel in B was plotted every 5 s to give the respective colored lines in C. The fluo-
rescence of the cytosolic areas (yellow, red and blue lines) decreased, and that of the nuclear areas (green, magenta and white lines) increased, 
after addition of forskolin. The fluorescence decrease began to reverse 1 min after removal of forskolin. The reversal was prevented when the 
cells were exposed to 1 uM FK506 10 min before and during the experiment; typical fluorescence ratio in the presence of FK506 are shown in 
C by a slashed line which shows the averaged fluorescence ratios for 7 cytosolic areas. The effect of forskolin was completely blocked in both 
areas when the cells were exposed to 1 uM Ff-89 10 min before, and during, the experiment; typical fluorescence ratios in the presence of H-89 
are shown in C by black lines which are smoothed to differentiate individual curves. The lower 4 panels in B show pseudo color fluorescence 
ratio images at the indicated times. The scale on the colored bar indicates the fluorescence ratio. The white bar corresponds to 10 urn. 
only to simple reaction mixtures but also to complex mixtures, 
we then tested cell lysates from a neuroblastoma cell line, 
neuro2A (Fig. IB), and from a neuroblastomaX glioma hy-
brid cell line, NG108-15 (data not shown), and found that 
these cell lysates were also able to phosphorylate ARII under 
the same conditions. Phosphorylation was confirmed both by 
HPLC analysis, using the phosphorylated fluorescent peptide 
as a standard (Fig. 1), and by sequencing of the isolated pep-
tide, and was inhibited by a specific PKA inhibitor, H-89 (0.2-
1 \iM, data not shown). No phosphorylation was detected 
under CaMKII activating conditions, despite the fact that 
ARII contains a consensus sequence for a CaMKII phosphor-
ylation site. These results indicate that phosphorylation is 
PKA-specific. 
3.2. Single cell analysis 
ARII was readily incorporated into NG108-15 cells when 
added to the extracellular medium and we therefore were able 
to apply our system to single cell analysis using NG108-15 
cells cultured on a poly-lysine-coated glass surface. The cells, 
pre-loaded with ARII, were exposed to forskolin for 30 s (Fig. 
2). The fluorescence started to decrease 15-30 s after forskolin 
application, reached a minimum at 60-90 s, then returned 
gradually to normal within 7>-A min. Exposure to 0.1-1 mM 
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Fig. 3. L-Glutamate activation of PKA in primary cultures of hippocampal neurons. A (left panel) and B show the transmitted light images. 
The cells were loaded with DRII (shown in the fluorescence image in the right panel in A), then the cells in A were treated with 1 uM FK506 
from time —5 min to the end of the experiment; the cells in B were treated identically, but 100 uM of Rp-cAMPS, a PKA inhibitor was also 
included. At time 0, the cells were stimulated by a 30 s exposure to 100 uM L-glutamate (C). The averaged fluorescence ratios for the areas in 
21 yellow and blue squares in A and B, respectively, are shown in C, using the same colors. In the absence of the PKA inhibitor, cell fluores-
cence clearly decreased; this change was not seen in the presence of the inhibitor. The green circles in C show the averaged fluorescence ratios 
for the areas in 21 in the same experiment as A but without FK506. (D): pseudo color fluorescence ratio images, at the indicated times, of the 
cells shown in A. The colored bar in C indicates the fluorescence ratio. The white bar in A (left panel) corresponds to 50 urn. 
dibutylyl cAMP also caused a decrease in fluorescence inten- forskolin-induced fluorescence decrease to be marked in the 
sity. Nuclear staining showed the ARII incorporation and its cytosol around the nucleus (Fig. 2A). The fluorescence de-
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crease was inhibited when the cells were exposed to 1 n,M H-
89 before and during the experiment, indicating that it was 
due to PKA activation. In some cases, the fluorescence de-
crease in the cytosolic area was followed by increased fluores-
cence in the nucleus (Fig. 2B, C), the increase starting 30 s 
after forskolin application, peaking at 90-120 s, then gradu-
ally declining, with the fluorescence at 6 min still being higher 
than in the untreated cell. As the catalytic domain of PKA 
translocates to the nucleus [4-7], a possible explanation for 
the fluorescence increment in the nucleus is the nuclear trans-
location of the fluorescence substrate in association with the 
catalytic domain although the association remains to be 
proved. The nuclear fluorescence increase was also inhibited 
by pretreatment with 1 |xM H-89, again indicating that the 
reaction is PKA-speciflc (Fig. 2C). It should be noted that if 
the large fluorescence increase is caused by the substrate trans-
location, the amount of the translocated substrate is likely to 
be small because of the following reason. As we measure the 
ratio of the fluorescence at individual time point to that at 
initial time, even a small change in nuclear content would 
cause a large change in the ratio, since only a small amount 
of substrate is initially present in the nucleus. Since the fluo-
rescence decrease in the cytosol ( > 10%) was larger than the 
difference in fluorescence intensity seen with the cell-free sys-
tem (3.3%), possible effects of substrate outflow on fluores-
cence changes in the cytosol cannot be excluded and the sys-
tem cannot therefore precisely measure phosphorylation of 
substrate. However, since the reactions in the cytosol and 
nucleus were both inhibited by a PKA inhibitor, they do 
reflect changes in the magnitude of PKA activity. We expected 
the return of fluorescence intensity, seen following the cyto-
solic decrease, to be due to dephosphorylation of the P-ARII 
produced, since calcineurin specifically dephosphorylates the 
original phosphorylated peptide [14] and when the cells were 
treated with a calcineurin inhibitor, FK506 (1 uM) before, 
and during, forskolin exposure, this reversal was indeed pre-
vented (blue slashed line in Fig. 2C). Increased cytosolic levels 
of cAMP may possibly activate calcineurin indirectly. These 
results suggest that calcineurin and the catalytic domain of 
PKA are co-localized, or closely localized, consistent with 
the report of Coghlan et al. [16] that both enzymes interact 
with the same anchor protein. We have also developed an 
imaging system for calcineurin activity, using a phosphory-
lated substrate (manuscript in preparation). It has been re-
ported that the catalytic domain of PKA translocates to the 
nucleus [4-7] and phosphorylates transcription factors, such 
as CREB [1], leading to expression of the specific gene, and 
calcineurin may act by modulating such gene expression by 
reversing the PKA-mediated phosphorylation. Co-localization 
would therefore be advantageous for rapid modulation of a 
common substrate. 
3.3. PKA activity in primary cultures of hippocampal neurons 
As described above, we succeeded in observing the dynam-
ics of PKA in neuroblastoma cells following stimulation 
which resulted in an increase in levels of intracellular 
cAMP. However, in the case of primary neuron cultures, 
very little ARII incorporation was seen (data not shown). 
To overcome this problem, we increased the hydrophobicity 
of the substrate by substituting 2 amino acid residues (Ala-88 
and Lys-89) from the rat skeletal muscle RII19 sequence into 
the bovine cardiac muscle-derived ARII and also substituting 
an additional 2 residues (Leu-86 and Ala-90); this modified 
peptide was then conjugated to DACM, yielding the conju-
gate DRII (Table 1). DRII had similar characteristics to ARII 
when tested in the cell-free PKA systems, except that its fluo-
rescence emission peak is at 475 nm (excitation at 386 nm). 
The DRII fluorescence decreased by 4.0% on phosphoryla-
tion. However, in contrast to ARII, it was readily incorpo-
rated into primary cultures of hippocampal neurons, as well 
as neuroblastomas, and was ubiquitously distributed through-
out the cell (Fig. 3A). When the cell was exposed to dibutylyl 
cAMP, the fluorescence throughout the cell decreased (data 
not shown); similar results were obtained when the cell was 
exposed to 100 u,M L-glutamate in the presence of the calci-
neurin inhibitor, FK506 (Fig. 3). Both reactions were com-
pletely inhibited by a specific PKA inhibitor, Rp-cAMPS. The 
fluorescence decrease was markedly inhibited when FK506 
was not present in the reaction mixture (green circles in Fig. 
3C), and in some cases, a slight increase in fluorescence was 
seen. Thus, substrate phosphorylation was enhanced when the 
cells were exposed to FK506 before, and during, the experi-
ment, again suggesting a close association between PKA and 
calcineurin and high basal activity of calcineurin in this cell. 
In a separated experiment, the cAMP concentration of pri-
mary hippocampal neuron cultures increased from 3.5 ±0.80 
(average ± S.E.M., n-1) to 7.3 ± 2.38 (n=7) pmol/mg cellular 
protein (P<0.01 by -F-test) following stimulation with 100 
|0.M glutamate for 7 min at 37°C. Since the hippocampal neu-
ron possesses glutamate receptors that open Ca2+ channels 
and increase the intracellular Ca2+ level, activation of PKA 
by glutamate probably occurs via activation of a Ca2+/calm-
odulin-dependent adenylate cyclase. Like glutamate stimu-
lated increment of intracellular Ca2+ level in the same cell 
[17], the increment of intracellular cAMP level should show 
spatial heterogeneity in the cell. Tsuji et al. [18] have shown a 
transient glutamate-induced increase in cAMP levels in cul-
tured spinal cord neurons, while Xia et al. [19] have reported 
enrichment of Ca2+/CaM-sensitive type I adenylate cyclase 
mRNA in the hippocampus and it is possible that this may 
be the enzyme responsible for the cAMP production. 
In summary, we have shown that dynamics of PKA activity 
in living neural cells was successfully visualized by fluores-
cence microscpic image processing using novel fluorescent 
substrates and that PKA in hippocampal neuron was acti-
vated by L-glutamate. 
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